TAHIR AHMED
Medical Practice in Miami, FL

5980865, Nov 9, 1999

Aug 4, 1997

8/904565

Tahir Ahmed - Coral Gables FL

Baker Norton Pharmaceuticals, Inc. - Miami FL

A61K 912

424 45

A method of treating a mammalian patient suffering from or prone to a condition characterized by late phase allergic reactions, airway hyperresponsiveness or inflammatory reactions, e. g. , asthma, allergic rhinitis, allergic dermatitis, allergic conjunctivitis, inflammatory bowel disease or rheumatoid arthritis, comprising the administration to the patient of an oral, parenteral, intrabronchial, topical, intranasal or intraocular pharmaceutical composition containing in each dose about 0. 005 to about 1. 0 mg per kilogram of patient body weight of ultra-low molecular weight heparins (ULMWH) or other sulfated polysaccharides having average molecular weights of about 1,000-3,000 daltons. Suitable inhalant and other pharmaceutical compositions for use in the novel treatment method are also disclosed.

5690910, Nov 25, 1997

Aug 18, 1995

8/516786

Tahir Ahmed - Coral Gables FL
Samuel Broder - Ft. Lauderdale FL
John K. Whisnant - Ft. Lauderdale FL

Baker Norton Pharmaceuticals, Inc. - Miami FL

A61K 912

424 45

A method of treating a patient suffering from antigen-induced asthma who has been challenged with an antigen, or providing chronic treatment to an asthma patient to reduce airway hyperresponsiveness, comprising intrabronchial administration to the patient of a pharmaceutical composition containing in each dose about 0. 05 to about 1. 0 mg of ultra-low molecular weight heparins (ULMWH), having an average molecular weight of 3,000 daltons or less, per kilogram of patient body weight, Inhalant pharmaceutical compositions for use in the novel treatment method are also provided.

7056898, Jun 6, 2006

Apr 16, 2002

10/123979

Tahir Ahmed - Coral Gables FL, US
Gregory Smith - N. Miami FL, US

Baker Norton Pharmaceuticals, Inc. - Miami FL

A61K 31/7024, C07H 11/04, C07H 13/12

514 53, 536117, 536118

Provided are compounds and compositions thereof that are useful for treating inflammation, particularly pulmonary inflammations including asthma and asthma-related pathologies such as allergy. Also provided are methods for using such compounds and compositions of the invention to treat patients suffering from, or predisposed to develop inflammation.

2013020, Aug 8, 2013

Oct 27, 2011

13/880875

Tahir Ahmed - Coral Gables FL, US
William Abraham - Miami FL, US

OPKO Health, Inc. - Miami FL

C13K 13/00, A61K 45/06, A61K 31/7016

514 53, 53612313

Hypersulfated disaccharides of formula I and other hypersulfated disaccharides disclosed herein are used to treat diseases or conditions associated with human neutrophil elastase imbalances. The disaccharides and/or intermediates useful to prepare such compounds are prepared from heparin. The diseases and conditions which are treated with a compound of formula I include chronic obstructive pulmonary disorder (COPD) and cystic fibrosis (CF). The formulations are delivered to the lungs in an aerosol formulation or dry powder means or via nebulization. Oral forms are also suitable.

2013034, Dec 26, 2013

Aug 28, 2013

14/011807

Tahir AHMED - Coral Gables FL, US

OPKO Health, Inc. - Miami FL

A61K 31/7016

514 53

Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The compounds are formulated with agents that enhance the oral delivery of the hypersulfated disaccharides. The delivery agents are selected from the group consisting of natural or synthetic polymers having ionic side chains as well as other compounds or types of compounds that improve the bioavailability of the disaccharides relative to delivery of the drug without such agents. The hypersulfated disaccharides are made from heparin or salts thereof.

6284800, Sep 4, 2001

Mar 13, 1998

9/042344

Samuel Broder - Weston FL
Tahir Ahmed - Coral Gables FL

Baker Norton Pharmaceuticals, Inc. - Miami FL

A61K 31135, A61K 3140

514652

The present invention comprises methods and compositions for the treatment of bronchorestrictive disorders, including asthma, in humans or animals. The methods and compositions are effective in treatment of inflammatory responses, such as those found in asthma and other related pathologies.

2011024, Oct 6, 2011

Mar 29, 2011

13/074549

Tahir AHMED - Coral Gables FL, US

OPKO Health, Inc. - Miami FL

A61K 31/7024, C07H 11/04, C07H 11/00, A61P 29/00, A61P 11/06, A61P 37/08, A61P 31/06, A61P 11/00, A61P 19/02, A61P 17/00, A61P 1/00

514 53, 536117, 536118

Hypersulfated disaccharides, preferably octasulfated sucrose, with utility in asthma or asthma related disorders are disclosed. The compounds may optionally be formulated with pharmaceutically acceptable excipients or delivery agents. The delivery agents are selected from the group consisting of natural or synthetic polymers, aerosols or other vehicles that facilitate the delivery or administration of the drug. The hypersulfated disaccharides are made from carbohydrate starting materials. Ion exchange or other suitable synthetic processes may be utilized to prepare the pharmaceuticals. The hypersulfated disaccharides are useful as anti-inflammatory agents.